[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354094-105":59,"doc-detail-354094-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","case-report-complete-metabolic-responses-to-trastuzumabderuxtecan-in-her2-altered-solid-tumors-two-illustrative-cases","Case Report - Complete metabolic responses to trastuzumab–deruxtecan in HER2-altered solid tumors - two illustrative cases","","Human epidermal growth factor receptor-2 (HER2) alterations are emerging therapeutic targets across multiple solid tumors, yet complete metabolic responses (CMRs) with the HER2-directed antibody-drug conjugate trastuzumab–deruxtecan (T-DXd) are uncommon. Two metastatic HER2-driven patients achieved CMRs after T-DXd: one with HER2 exon 20–insertion non-small cell lung cancer and brain involvement, and another with HER2-expressing micropapillary urothelial carcinoma. Findings highlight deep remissions and the role of FDG-PET/CT.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/case-report-complete-metabolic-responses-to-trastuzumabderuxtecan-in-her2-altered-solid-tumors-two-illustrative-cases/354094/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/case-report-complete-metabolic-responses-to-trastuzumabderuxtecan-in-her2-altered-solid-tumors-two-illustrative-cases/354094.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main clinical focus of this case report?","Question",{"text":113,"@type":114},"The report evaluates the ability of trastuzumab–deruxtecan (T-DXd) to produce complete metabolic responses in HER2-altered solid tumors assessed by FDG-PET/CT.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which HER2-altered cancers are covered by the two illustrative cases?",{"text":118,"@type":114},"Case 1 is metastatic non-small cell lung cancer with a HER2 exon 20 insertion; Case 2 is metastatic micropapillary urothelial carcinoma with HER2 expression.",{"name":120,"@type":111,"acceptedAnswer":121},"How were responses monitored and what were the outcomes under T-DXd?",{"text":122,"@type":114},"Responses were assessed using FDG-PET/CT. Both patients achieved deep remissions, with complete metabolic resolution of lesions, including a brain metastasis in the first case.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354094,1790198399,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","TYPE Case Report  \nPUBLISHED 17 April 2026  \nDOI 10.3389/fimmu.2026.1752694  \nOPEN ACCESS  \nEDITED BY  \nSergei Kusmartsev,  \nUniversity of Florida, United States  \nREVIEWED BY  \nWei Ke,  \nRutgers, The State University of New Jersey, United States  \nAli Kaan Güren,  \nMarmara University, Türkiye  \n*CORRESPONDENCE  \nKarim Amrane  \n [kamrane@ch-morlaix.fr](kamrane@ch-morlaix.fr)  \nRECEIVED 23 November 2025  \nREVISED 16 March 2026  \nACCEPTED 24 March 2026  \nPUBLISHED 17 April 2026  \nCITATION  \nLe Meur C, Le Roux P-Y, Alemany P, Chauvelot F, Pradier O, Niel C, Bellange A, Chouaid C, Massard C and Amrane K (2026) Case Report: Complete metabolic responses to trastuzumab– deruxtecan in HER2-altered solid tumors: two illustrative cases.  \nFront. Immunol. 17:1752694 .  \ndoi: 10.3389/fimmu.2026.1752694  \nCOPYRIGHT  \n© 2026 Le Meur, Le Roux, Alemany, Chauvelot, Pradier, Niel, Bellange, Chouaid, Massard and Amrane. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCase Report: Complete metabolic responses to trastuzumab–deruxtecan in HER2-altered solid tumors: two illustrative cases  \nColine Le Meur 1, Pierre-Yves Le Roux 2,3, Pierre Alemany 4, Fr´ed´eric Chauvelot 5, Olivier Pradier 1, Cl´emence Niel 6, Alex Bellange 6, Christos Chouaid 7, Christophe Massard 8 and Karim Amrane 6,8*  \n1 Department of Radiotherapy, University Hospital of Brest, Brest, France, 2 Department of Nuclear Medicine, University Hospital of Brest, Brest, France, 3 UMR Inserm 1304 GETBO, IFR 148, Universite´ de Bretagne Occidentale, Brest, France, 4 Department of Pathology, Ouest Pathologie Brest, Brest, France, 5 Department of Pharmacy, Regional Hospital of Morlaix, Morlaix, France, 6 Department of Oncology, Regional Hospital of Morlaix, Morlaix, France, 7 Department of Pulmonology, Centre Hospitalier Intercommunal (CHI) Cre´ teil, Cre´ teil, France; Institut Mondor de Recherche Biome´ dicale, U955 Inserm-Universite´ Paris Est Cre´teil, Cre´teil, France, 8 De´ partement d’ Innovation The´rapeutique et des Essais Pre´coces (DITEP), Gustave Roussy, Universite´ Paris Saclay, Villejuif, France  \nBackground: Human epidermal growth factor receptor-2 (HER2) alterations, including activating mutations and gene ampliﬁcation, are emerging therapeutic targets in several solid tumors. Trastuzumab–deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate (ADC), has demonstrated antitumor activity across multiple HER2-altered cancers. However, complete metabolic responses (CMRs) remain uncommon, particularly when assessed by 2-deoxy-2-[18F]ﬂuoro-D-glucose positron emission tomography-computed tomography (FDGPET/CT) .  \nPresentation of cases: We report two patients with metastatic HER2-driven malignancies who achieved a CMR under T-DXd. The ﬁrst case concerns a patient with metastatic non-small cell lung cancer harboring a HER2 exon 20 insertion who progressed on chemoimmunotherapy and HER2-directed antibodies. Third-line T-DXd led to rapid metabolic improvement and complete resolution of all lesions, including a brain metastasis. The second case involves a patient with metastatic micropapillary urothelial carcinoma with HER2 expression, refractory to platinum chemotherapy, avelumab maintenance, and enfortumabvedotin. T-DXd induced an early partial metabolic response (PMR), followed by aconﬁrmed CMR after four cycles.  \nConclusion: These two observations illustrate the capacity of T-DXd to induce deep and complete metabolic remissions in distinct HER2-altered solid tumors. They support further development of HER2-targeted ADCs beyond traditional indications and highlight the value of F","cbCaip84bN8xJt0T","https://ap.wps.com/l/cbCaip84bN8xJt0T","pdf",5683132,"English","# Introduction\n# Presentation of cases\n## Case 1\n## Case 2\n# Conclusion","[{\"question\":\"What is the main clinical focus of this case report?\",\"answer\":\"The report evaluates the ability of trastuzumab–deruxtecan (T-DXd) to produce complete metabolic responses in HER2-altered solid tumors assessed by FDG-PET/CT.\"},{\"question\":\"Which HER2-altered cancers are covered by the two illustrative cases?\",\"answer\":\"Case 1 is metastatic non-small cell lung cancer with a HER2 exon 20 insertion; Case 2 is metastatic micropapillary urothelial carcinoma with HER2 expression.\"},{\"question\":\"How were responses monitored and what were the outcomes under T-DXd?\",\"answer\":\"Responses were assessed using FDG-PET/CT. Both patients achieved deep remissions, with complete metabolic resolution of lesions, including a brain metastasis in the first case.\"}]","Case Report - Complete metabolic responses to trastuzumab–deruxtecan in HER2-altered solid tumors - two illustrative cases | PDF",1790108879,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45bd45d51a15f96008b5a707db54d5d8.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e149a7c6c1fc5f0da151c6272fd8df93.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ada0bc7ec766fed821e5842665b19dd.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55a5fc1eaedfe926f74bc848988a6c44.webp",980,1385]